The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. The main question it aims to answer is to determine the persistence of the immune response induced by the GBS-NN/NN2 vaccine by measuring antibody concentrations. Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination.
This is a follow-up study to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine. No vaccine or placebo will be administered. A single 10 mL blood sample will be collected from participants, every year, for a maximum of 4 years. Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination. Only participants that received two doses GBS-NN/NN2 in MVX0002 and all participants that received a single dose in MVX0003 will be eligible. Hence, participants will have received: One dose of GBS-NN/NN2 prior to this study, i.e., participants from MVX0003 who had not received GBS-NN/NN2 in MVX0002 and received a single dose in MVX0003. Or two doses of GBS-NN/NN2 prior to this study, i.e., participants from MVX0002 who had received two doses of GBS-NN/NN2 in MVX0002 and did not take part in MVX0003. Or three doses of GBS-NN/NN2 prior to this study, i.e., participants from MVX0003 who had received two doses of GBS-NN/NN2 in MVX0002 and received a single dose in MVX0003.
Study Type
OBSERVATIONAL
Enrollment
29
GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil, Pentrebach Merthyr Tydfil CF48 4DR, United Kingdom
Antibody Concentration Specific for GBS-NN and GBS-NN2
Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for GBS-NN and GBS-NN2 will be collected during the study.
Time frame: Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alpha like proteins (Alp): AlpCN
Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study
Time frame: Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alp: RibN
Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study
Time frame: Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alp: Alp1N
Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study
Time frame: Baseline (Year 0), Years 1, 2, 3, 4
Ig G Antibody Responses Specific to Alp: Alp2-3N
Pharmacodynamic (PD) blood samples (10 mL) for antibody concentration specific for AlpCN, RibN, Alp1N and Alp2/3N will be collected during the study
Time frame: Baseline (Year 0), Years 1, 2, 3, 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.